

NATIONAL COLLABORATING CENTRE FOR CANCER (NCC-C)

Myeloma

Fourth Guideline Development Group (GDG) meeting

23rd July 2014

Board Room, NCC-C, Park House, Greyfriars Road, Cardiff

GROUP MEMBERSHIP & ACTION LIST

GDG Members	
Curly Morris (CM)	Monica Morris (MM)
Guy Pratt (GP)	Sam Ahmedzai (SA)
Matthew Jenner (MJ)	Nicola Montacute (NMo)
Matthew Streetly (MS)	Alan Chant (ACh)
John Snowden (JS)	Andrea Guy (AG)
Jane Woodward (JW)	Lesley Roberts (LR)
NCC-C staff	
Angela Bennett (AB)	Kim Lewis (KL)
Nathan Bromham (NB)	Elise Hasler (EH)
Matthew Prettyjohns (MP)	Angharad Morgan (AM)
James Hawkins (JH)	Andrew Champion (AC)
John Graham (JG)	
NICE staff	
Katie Perryman-Ford (KPF)	Anne-Louise Clayton (ALC)
Apologies	
Hamdi Sati (HS)	Nicola Mulholland (NM)

REPORTS OF DISCUSSIONS AT THE MEETING

1. Introductions

- CM welcomed everyone to the 4th meeting of the Myeloma GDG including Anne-Louise Clayton, senior medical editor from NICE who will be presenting to the GDG on how to word recommendations in NICE guidelines. Apologies were received from Hamdi Sati and Nicola Mulholland.

3. Declarations of Interest

The following declarations of interest were declared prior to the meeting:

- MJ declared that he is the chief investigator for the MUK 4 trial investigating bortezomib and dexamethasone with vorinostat in relapsed myeloma and is involved in designing the trial protocol. The trial is funded by Myeloma UK. This interest was categorised as non-personal pecuniary (specific TBC once clinical questions have been finalised) meaning that MJ can participate in discussion of all guideline topics as the trial is not funded by the pharmaceutical industry.
- MJ declared that he is local principle investigator for the Pollux study, a randomised phase III study investigating lenalidomide and dexamethasone +/- daratumab in relapsed myeloma. The study is funded by Janssen. This interest was categorised as non-personal pecuniary (specific TBC once clinical questions have been finalised) meaning that MJ can participate in discussion of all guideline topics as he has no

supervisory responsibly on the trial and was not involved in designing the trial protocol.

- MJ declared that he will receive reimbursement of travel and subsistence expenses and an honorarium from Takeda UK for participating in an advisory board on myeloma in October 2014. This interest was categorised as personal pecuniary, non-specific meaning that MJ can participate in discussion of all guideline topics as interventions manufactured by Takeda UK are not being investigated by the guideline.
- MM declared that she will receive reimbursement of travel and subsistence expenses from Myeloma UK for taking part in ongoing work on an advisory board for the Myeloma UK research strategy. This interest was categorised as personal pecuniary, non-specific meaning that MM can participate in discussion of all guideline topics as payment of expenses was not beyond reasonable amounts.

The following declarations of interest were declared at to the meeting:

- CM declared that he will receive reimbursement of travel and subsistence expenses from The Binding Site Ltd to attend their conference in Edinburgh in April 2015. This interest was categorised as personal pecuniary, non-specific meaning that CM can participate in discussion of all guideline topics as payments of expenses was not beyond reasonable amounts.

The GDG were reminded that if they take on any new interests, these must be declared to the NCC-C as soon as they happen so that the necessary action can be taken.

4. Discussions

The GDG discussed the evidence and agreed the recommendations and LETR tables for topics Q and L1.

The GDG discussed and finalised review protocol for topic A.

5. Close of meeting

CM thanked the GDG for their input to the meeting, reminded them that the next meeting would be on **Wednesday 10th September 2014**, starting at 10.30 in the Board Room, NCC-C, Cardiff and closed the meeting.